Assessment of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SCH 900518 in Naive or Treatment-Experienced Subjects Infected With Hepatitis C Virus Genotype 1 (Protocol No. P04695).

Trial Profile

Assessment of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SCH 900518 in Naive or Treatment-Experienced Subjects Infected With Hepatitis C Virus Genotype 1 (Protocol No. P04695).

Completed
Phase of Trial: Phase I

Latest Information Update: 08 May 2014

At a glance

  • Drugs Narlaprevir (Primary) ; Peginterferon alfa-2b; Ribavirin; Ritonavir
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Schering-Plough
  • Most Recent Events

    • 06 Mar 2010 Actual patient number (41) added as reported by ClinicalTrials.gov.
    • 06 Mar 2010 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health).
    • 28 Apr 2009 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top